Brett D. Story
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brett D. Story has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Sara M. Thomasy
Department of Surgical and Radiological Sciences, School of Veterinary Medicine University of California, Davis Davis California USA
2 shared publications Ala Moshiri
Department of Ophthalmology and Vision Science, School of Medicine, University of California, Davis
1 shared publicationAna C. Raposo
Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis
1 shared publicationAna Ripolles-Garcia
Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis
1 shared publication- Brad Fortune
Discoveries in Sight Research Laboratories, Devers Eye Institute and Legacy Research Institute, Legacy Health, Portland, Oregon, United States
1 shared publication Brian C. Leonard
Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, Davis
1 shared publication
Latest Publications
- Open Access
- 11 June 2026
- Published by Elsevier in Molecular Therapy
- Vol. 34 (9) , 5498-5509
Cerebrospinal Delivery of a Bidirectional Aav9 Vector Improves Optic Nerve and Retinal Pathology in a Sheep Model of Tay-Sachs Disease
- 11 June 2026
- Published by Elsevier in Molecular Therapy
- Vol. 34 (9) , 5498-5509
Open AccessCerebrospinal Delivery of a Bidirectional Aav9 Vector Improves Optic Nerve and Retinal Pathology in a Sheep Model of Tay-Sachs Disease
- Open Access
- 15 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (16)
Rhesus macaques with an OPA1 mutation demonstrate features of autosomal dominant optic atrophy
Autosomal dominant optic atrophy (ADOA) is an inherited optic neuropathy primarily caused by mutations in OPA1 . We identified and defined a spontaneous nonhuman primate (NHP) model of ADOA using rhesus macaques heterozygous for a missense mutation ( OPA1 A8S). With ocular examinations, ophthalmic imaging, electroretinography, histopathology, immunohistochemistry, and transmission electron microscopy (TEM), we documented retinal nerve fiber layer (RNFL) thinning, retinal ganglion cell (RGC) loss and dysfunction, OPA1 mislocalization, and reduced axonal mitochondrial density in affected macaques. Our investigation revealed substantial phenotypic variability among affected macaques, shedding light on the pathogenesis of ADOA. The retinas were evaluated using techniques such as spectral-domain optical coherence tomography and fundus photography facilitating observation of structural changes in the retina and optic nerve. Thinning of the RNFL and optic nerve head degeneration, hallmark features of ADOA, were observed in affected macaques. Decreased RGC function in the OPA1 heterozygotes was demonstrated with pattern electroretinography. Histopathological analysis and immunohistochemical staining of postmortem retinal tissue suggested RGC loss in the papillomacular bundle, with reduced OPA1 and mitochondria in the RGC axons, indicating dysfunctional mitochondrial dynamics and reduced function consistent with ADOA. Ultrastructural changes were evident with TEM including dysmorphic mitochondria, axonal loss, myelin disruption, and hypertrophic astrocytic processes. The observed similar pattern of RGC loss and dysfunction coupled with phenotypic heterogeneity in our NHP model reflects the clinical variability observed in human ADOA patients indicating that therapeutic interventions in this foveate model will likely translate to the human condition.
- 15 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (16)
Open AccessRhesus macaques with an OPA1 mutation demonstrate features of autosomal dominant optic atrophy
Autosomal dominant optic atrophy (ADOA) is an inherited optic neuropathy primarily caused by mutations in OPA1 . We identified and defined a spontaneous nonhuman primate (NHP) model of ADOA using rhesus macaques heterozygous for a missense mutation ( OPA1 A8S). With ocular examinations, ophthalmic imaging, electroretinography, histopathology, immunohistochemistry, and transmission electron microscopy (TEM), we documented retinal nerve fiber layer (RNFL) thinning, retinal ganglion cell (RGC) loss and dysfunction, OPA1 mislocalization, and reduced axonal mitochondrial density in affected macaques. Our investigation revealed substantial phenotypic variability among affected macaques, shedding light on the pathogenesis of ADOA. The retinas were evaluated using techniques such as spectral-domain optical coherence tomography and fundus photography facilitating observation of structural changes in the retina and optic nerve. Thinning of the RNFL and optic nerve head degeneration, hallmark features of ADOA, were observed in affected macaques. Decreased RGC function in the OPA1 heterozygotes was demonstrated with pattern electroretinography. Histopathological analysis and immunohistochemical staining of postmortem retinal tissue suggested RGC loss in the papillomacular bundle, with reduced OPA1 and mitochondria in the RGC axons, indicating dysfunctional mitochondrial dynamics and reduced function consistent with ADOA. Ultrastructural changes were evident with TEM including dysmorphic mitochondria, axonal loss, myelin disruption, and hypertrophic astrocytic processes. The observed similar pattern of RGC loss and dysfunction coupled with phenotypic heterogeneity in our NHP model reflects the clinical variability observed in human ADOA patients indicating that therapeutic interventions in this foveate model will likely translate to the human condition.
- Open Access
- 10 October 2023
- Published by Wiley in Veterinary Ophthalmology
- Vol. 27 (3) , 248-255
Additional evidence supports GRM6 p.Thr178Met as a cause of congenital stationary night blindness in three horse breeds
Congenital stationary night blindness (CSNB) is an ocular disorder characterized by nyctalopia. An autosomal recessive missense mutation in glutamate metabotropic receptor 6 (GRM6 c.533C>T, p.(Thr178Met)), called CSNB2, was previously identified in one Tennessee Walking Horse and predicted to reduce binding affinity of the neurotransmitter glutamate, impacting the retinal rod ON‐bipolar cell signaling pathway. Thus, the first aim was to identify the allele frequency (AF) of CSNB2 in breeds with reported cases of CSNB and breeds closely related to the Tennessee Walking Horse. The second aim was to perform ocular examinations in multiple breeds to confirm the link between genotype and CSNB phenotype. In evaluating 3518 horses from 14 breeds, the CSNB2 allele was identified in nine previously unreported breeds. The estimated AF was highest in pacing Standardbreds (0.17) and lowest in American Quarter Horses (0.0010). Complete ophthalmic examinations and electroretinograms (ERG) were performed on 19 horses from three breeds, including one CSNB2 homozygote from each breed. All three CSNB2/CSNB2 horses had an electronegative ERG waveform under scotopic light conditions consistent with CSNB. The remaining 16 horses (seven CSNB2/N and nine N/N) had normal scotopic ERG results. All horses had normal photopic ERGs. This study provides additional evidence that GRM6 c.533C>T homozygosity is likely causal to CSNB in Tennessee Walking Horses, Standardbreds, and Missouri Fox Trotting Horses. Genetic testing is recommended for breeds with the CSNB2 allele to limit the production of affected horses. This study represents the largest across‐breed identification of CSNB in the horse and suggests that this disorder is likely underdiagnosed.
- 10 October 2023
- Published by Wiley in Veterinary Ophthalmology
- Vol. 27 (3) , 248-255
Open AccessAdditional evidence supports GRM6 p.Thr178Met as a cause of congenital stationary night blindness in three horse breeds
Congenital stationary night blindness (CSNB) is an ocular disorder characterized by nyctalopia. An autosomal recessive missense mutation in glutamate metabotropic receptor 6 (GRM6 c.533C>T, p.(Thr178Met)), called CSNB2, was previously identified in one Tennessee Walking Horse and predicted to reduce binding affinity of the neurotransmitter glutamate, impacting the retinal rod ON‐bipolar cell signaling pathway. Thus, the first aim was to identify the allele frequency (AF) of CSNB2 in breeds with reported cases of CSNB and breeds closely related to the Tennessee Walking Horse. The second aim was to perform ocular examinations in multiple breeds to confirm the link between genotype and CSNB phenotype. In evaluating 3518 horses from 14 breeds, the CSNB2 allele was identified in nine previously unreported breeds. The estimated AF was highest in pacing Standardbreds (0.17) and lowest in American Quarter Horses (0.0010). Complete ophthalmic examinations and electroretinograms (ERG) were performed on 19 horses from three breeds, including one CSNB2 homozygote from each breed. All three CSNB2/CSNB2 horses had an electronegative ERG waveform under scotopic light conditions consistent with CSNB. The remaining 16 horses (seven CSNB2/N and nine N/N) had normal scotopic ERG results. All horses had normal photopic ERGs. This study provides additional evidence that GRM6 c.533C>T homozygosity is likely causal to CSNB in Tennessee Walking Horses, Standardbreds, and Missouri Fox Trotting Horses. Genetic testing is recommended for breeds with the CSNB2 allele to limit the production of affected horses. This study represents the largest across‐breed identification of CSNB in the horse and suggests that this disorder is likely underdiagnosed.
- 26 May 2021
- Published by Wiley in Veterinary Ophthalmology
- Vol. 24 (6) , 572-581
Long‐term results (>1 year) in 19 dogs treated with MicroPulse transscleral diode cyclophotocoagulation for refractory glaucoma
Objective: To report the long‐term (>1 year) outcome of MicroPulse transscleral diode cyclophotocoagulation (MP‐TSCP) in dogs.Animals Studied: Client owned dogs that underwent MP‐TSCP at a veterinary referral center.Procedure: Retrospective study of 19 dogs treated with MP‐TSCP. Dogs were evaluated at a median follow‐up time of 30.5 months postoperatively. Reported outcomes were intraocular pressure (IOP), retention or loss of vision, number of medications, and additional procedures performed. Variables associated with time to treatment failure were evaluated.Results: Data from 19 dogs (24 eyes) was available. Median laser settings employed were 140 s and 2200 mW at 31.3% duty cycle. Long‐term postoperative IOP was lower than preoperative IOP values (14 mmHg (IQR = 22 mmHg, range: 4–52 mmHg) versus 30 mmHg (IQR = 31 mmHg, range: 8–62 mmHg), respectively). Laser settings >2000 mW were associated with a significantly longer time to reported failure. MP‐TSCP was the sole therapy performed in 16/24 eyes resulting in long‐term IOP control in 13/24 eyes and retention of vision in 6 of the 14 sighted eyes. Repeat MP‐TSCP was performed in 10/24 eyes. Eight of 24 eyes required additional procedures with long‐term IOP control in 4/8 eyes.Conclusions: MicroPulse transscleral diode cyclophotocoagulation can be an effective treatment for refractory glaucoma in select cases. Higher laser settings increased time to reported failure, whereas age, glaucoma type, and preoperative IOP did not affect survival. MP‐TSCP as sole therapy or coupled with additional glaucoma procedures controlled the IOP in 70% of cases.
- 26 May 2021
- Published by Wiley in Veterinary Ophthalmology
- Vol. 24 (6) , 572-581
Long‐term results (>1 year) in 19 dogs treated with MicroPulse transscleral diode cyclophotocoagulation for refractory glaucoma
Objective: To report the long‐term (>1 year) outcome of MicroPulse transscleral diode cyclophotocoagulation (MP‐TSCP) in dogs.Animals Studied: Client owned dogs that underwent MP‐TSCP at a veterinary referral center.Procedure: Retrospective study of 19 dogs treated with MP‐TSCP. Dogs were evaluated at a median follow‐up time of 30.5 months postoperatively. Reported outcomes were intraocular pressure (IOP), retention or loss of vision, number of medications, and additional procedures performed. Variables associated with time to treatment failure were evaluated.Results: Data from 19 dogs (24 eyes) was available. Median laser settings employed were 140 s and 2200 mW at 31.3% duty cycle. Long‐term postoperative IOP was lower than preoperative IOP values (14 mmHg (IQR = 22 mmHg, range: 4–52 mmHg) versus 30 mmHg (IQR = 31 mmHg, range: 8–62 mmHg), respectively). Laser settings >2000 mW were associated with a significantly longer time to reported failure. MP‐TSCP was the sole therapy performed in 16/24 eyes resulting in long‐term IOP control in 13/24 eyes and retention of vision in 6 of the 14 sighted eyes. Repeat MP‐TSCP was performed in 10/24 eyes. Eight of 24 eyes required additional procedures with long‐term IOP control in 4/8 eyes.Conclusions: MicroPulse transscleral diode cyclophotocoagulation can be an effective treatment for refractory glaucoma in select cases. Higher laser settings increased time to reported failure, whereas age, glaucoma type, and preoperative IOP did not affect survival. MP‐TSCP as sole therapy or coupled with additional glaucoma procedures controlled the IOP in 70% of cases.